Private
5 months ago
13 Views

Asimov

AI Business
Boston, Massachusetts, USA
funded over $100 million

Category

AI Business

Asimov, founded in 2017, is a Boston-based synthetic biology company specializing in the design and programming of living cells. By integrating mammalian synthetic biology with computer-aided design and machine learning, Asimov develops tools to advance the design and manufacture of biologics and gene therapies. Their platform includes engineered host cells, a comprehensive library of genetic parts, and cloud-based software for designing and optimizing genetic systems, enabling precise control over cellular functions for therapeutic applications.

The company has attracted significant investment from both venture capital firms and strategic investors. In January 2023, Asimov announced $200 million in new funding, including a $175 million Series B led by Canada Pension Plan Investment Board (CPP Investments), with participation from Fidelity Management & Research Company, KDT, Casdin Capital, Pillar, and Andreessen Horowitz (a16z). This funding supports the expansion of Asimov’s tools and services in biologics, cell and gene therapies, and RNA.

Asimov’s uniqueness lies in its comprehensive approach to genetic design, combining state-of-the-art synthetic biology with computational tools to program living cells. Their platform enables the development of advanced therapies by providing precise control over gene expression and cellular behavior. This approach addresses critical challenges in biotechnology, such as optimizing protein production and developing effective gene therapies, by offering scalable and customizable solutions for complex biological systems.

Within the realm of artificial intelligence, Asimov operates in the category of AI-driven Synthetic Biology. Their technology leverages machine learning algorithms to predict and optimize genetic constructs, facilitating the design of living systems with desired functions. By integrating AI with synthetic biology, Asimov enhances the efficiency and accuracy of genetic engineering, paving the way for innovative therapeutic solutions.

 

 

Asimov is based in Boston, Massachusetts, USA. Specializing in the AI industry, Asimov pioneers innovative solutions and advancements in artificial intelligence. Asimov, funded over $100 million, is well-positioned to drive significant impact and growth in the AI sector. For more information, please visit asimov.com.

 

 

To claim this startup page, go to the Contact page and send us a message with your full name, startup name, job title, and startup email address. We will review your request and get back to you. Once verified, you can update your startup information.

Write a Review

Post as Guest
Your opinion matters
Minimum characters: 10
startupzone
Member since: 7 months
User is offline
See all ads
Add to favorites
Add to compare
Report abuse
© 2024 StartupZone.com. All rights reserved.